Home Blog Requirements of an EU PV system – Signal Management

Requirements of an EU PV system – Signal Management

by Alex Xuereb, QA/PV specialist @Quintian Pharma

GxP Compliance

Discover more

Find out how can PQE support your business

Get in touch with us

Challenges Faced by Marketing Authorization Holders in Signal Management for Pharmacovigilance Systems

A critical part of any pharmacovigilance (PV) system is the process of signal management. As per article 19 of the Commission Implementing Regulation (EU) No 520/2012, Marketing Authorization Holders (MAHs) are legally required to identify new or changing adverse events related to their medicinal product or Active Pharmaceutical Ingredient (API). 

The challenge comes when deciding on how to identify, validate and act on these new adverse events in an appropriately scientific manner.  
Requirements of an EU PV system_Site PQE (1)

Current MAHs Issues

Many MAHs are faced with the following issues: 

  • Huge quantities of safety data, often in the form of spontaneous Adverse Drug Reports (ADRs) or as Individual Case Safety Reports (ICSRs), are collected or available that can vary greatly in quality.
  • The data being collected is decentralized and does not have the luxury of being collected from a clinical trial where variables can be tightly monitored and compared to a control.
  • EU guidelines on signal management leave room for interpretation and innovation, as they often do. This can be difficult for untrained personnel who are looking to transpose these guidelines into their own functioning PV and signal management systems.

Read the full article on QuintianPharma.com

Are you ready for change?

PQE Group can support your business in reaching the compliance for your products as well as in implementing new procedures, tools and software.

To get more information or support, get in touch with us  or check our Quality Compliance dedicate page to find the most suitable solution for your company.


Connect with us

More on this topic

GxP Compliance
Features of radiopharmaceuticals production
22 Jan 2024

Features of radiopharmaceuticals production

Discover the essential features of radiopharmaceuticals production in this informative blog post.

GxP Compliance
mRNA product manufacturing: the future of biotech world
10 Nov 2023

mRNA product manufacturing: the future of biotech world

Covid-19 vaccines are an example for the success of mRNA technology, but not everyone may know that mRNA therapeutic products have been studied for decades

GxP Compliance
Inspection Readiness: What's Next?
10 Oct 2023

Inspection Readiness: What's Next?

Based on the 2023 EMA programming document, the forecast for the coming years is a recovery of coordination of inspections and certificate requests.